Endocrinology

Myeloma

Questions discussed in this category

For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?

For pts w/ eGFR between 30-60

1 Answer available

Do you routinely offer a bisphosphonate or denosumab to multiple myeloma patients without skeletal lesions?

Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).

2 Answers available

For patients with cancer receiving a bone-modifying agent (bisphosphonate or denosumab) who suffer a fracture requiring stabilization or reconstruction, how do you manage the bone-modifying agent peri-operatively?

Is there concern for impaired healing? Do you pause therapy and for how long?

1 Answer available

Is there any role for bisphosphonate or alternative bone-modifying agents use in SMM in the absence of other indications for its use?

1 Answer available

Papers discussed in this category

Leuk. Lymphoma, 2011 Feb 08

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

Cancer,

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Blood, 2013-10-24

The impact of response on bone-directed therapy in patients with multiple myeloma.

The Lancet. Oncology, 2011-08

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

The Lancet. Oncology, 2018-03

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Related Topics in Endocrinology